Roshan Shrestha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roshan Shrestha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Bradley Butler
Piedmont Transplant Services, Piedmont Hospital, Atlanta, GA
1 shared publicationCarlos Zayas
Piedmont Transplant Services, Piedmont Hospital, Atlanta, GA
1 shared publicationD. W. Joelson
Department of Transplantation, Piedmont Hospital, Atlanta, GA
1 shared publicationDavid M. S. Grunkemeier
1 shared publicationJody L. Jones
Piedmont Transplant Services, Piedmont Hospital, Atlanta, GA
1 shared publicationK. M. Kegley
Department of Transplantation, Piedmont Hospital, Atlanta, GA, USA
1 shared publication
Latest Publications
- Open Access
- 1 May 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (5) , 1325-1329
Fulminant Wilson's Disease Requiring Liver Transplantation in One Monozygotic Twin Despite Identical Genetic Mutation
- 1 May 2010
- Published by Elsevier in American Journal of Transplantation
- Vol. 10 (5) , 1325-1329
Open AccessFulminant Wilson's Disease Requiring Liver Transplantation in One Monozygotic Twin Despite Identical Genetic Mutation
- 1 April 2006
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 9 (2) , 133-144
Endoscopic treatment of biliary tract disease prior to orthotopic liver transplantation
- 1 April 2006
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 9 (2) , 133-144
Endoscopic treatment of biliary tract disease prior to orthotopic liver transplantation
- 1 January 2006
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 13 (1) , 162-164
Terbinafine-induced hepatic failure requiring liver transplantation
Drug‐induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%‐20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular‐cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine‐induced severe liver failure requiring liver transplantation. Liver Transpl 13:162–164, 2007. © 2006 AASLD.
- 1 January 2006
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 13 (1) , 162-164
Terbinafine-induced hepatic failure requiring liver transplantation
Drug‐induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%‐20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular‐cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine‐induced severe liver failure requiring liver transplantation. Liver Transpl 13:162–164, 2007. © 2006 AASLD.